The study was small — just 48 adults — and lasted just over two months, so it’s not the final word. But the results add to evidence that GLP-1 drugs like Ozempic might help with cravings for things ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

Inc. (NYSE American: PTN) has announced the completion of their Phase 2 clinical trial for an obesity treatment, marking a ...

Yo-yo dieting has significantly increased the risk of kidney disease in those with type 1 diabetes, regardless of body mass index and other traditional risk factors, according to a new study published ...

Type 1 diabetes has long been considered a disease of lean people, but obesity is becoming more common in that group as well ...

Scientist develop new equation for detecting hyperfiltration that incorporates age but not body surface area. Read more!

After a post mortem, his causes of death were given as pulmonary embolism, deep vein thrombosis, renal transplantation for chronic kidney disease, secondary to diabetic nephropathy and obesity.

(HealthDay News) — For patients with overweight or obesity and type 2 diabetes, dapagliflozin plus regular calorie restriction is associated with a significantly higher rate of remission of diabetes ...

Additionally, several other conditions that commonly occur alongside obesity — type 2 diabetes, high cholesterol, and metabolic syndrome — all increase your risk of developing MASH.